Details for: BRILINTA
Company: ASTRAZENECA CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02455005 | BRILINTA | TICAGRELOR | 60 MG | TABLET | ORAL |
| 02368544 | BRILINTA | TICAGRELOR | 90 MG | TABLET | ORAL |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Summary Safety Review - BRILINTA (ticagrelor) - Assessing the Potential Risk of Severe Skin Side Effects
Summary Safety Review - Brilinta (ticagrelor) - Assessing the Potential Risks of a Worsening of a Slow and Irregular Heartbeat (Bradyarrhythmia) and Partial or Complete Block in the Transmission of Heart Impulses (Second- and Third-Degree Atrioventricular Block)
Summary Safety Review - Brilinta (ticagrelor) - Assessing the Potential Risk of Central Sleep Apnea
Regulatory Decision Summary
Summary Safety Review - BRILINTA (ticagrelor) - Assessing the Potential Risk of Severe Skin Side Effects
Summary Safety Review - Brilinta (ticagrelor) - Assessing the Potential Risks of a Worsening of a Slow and Irregular Heartbeat (Bradyarrhythmia) and Partial or Complete Block in the Transmission of Heart Impulses (Second- and Third-Degree Atrioventricular Block)
Summary Safety Review - Brilinta (ticagrelor) - Assessing the Potential Risk of Central Sleep Apnea
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.